Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide

Abhinav Mathur* (Corresponding Author), Joakim Edman, Livia Liang, Neil Scott, Henry Watson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)


Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single-centre experience of 324 HC-treated MPN patients with long-term follow-up, compared to 47 MPN patients not on HC. Thirty-three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow-up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.
Original languageEnglish
Pages (from-to)1305-1309
Issue number4
Early online date2 Sept 2022
Publication statusPublished - 20 Nov 2022

Bibliographical note

Funding Information
This research was supported by NHS Grampian Endowment Fund (grant number: EA4075).

Data Availability Statement

The data that support the findings of this study are available upon request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Additional supporting information can be found online in the Supporting Information section at the end of this article.


  • essential thrombocythaemia
  • hydroxycarbamide
  • melanoma
  • myeloproliferative neoplasm
  • non-melanoma skin cancer
  • polycythemia vera


Dive into the research topics of 'Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide'. Together they form a unique fingerprint.

Cite this